Trial · NCT03504917
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline at Week 24 on the Vineland Adaptive Behavior Scales (Vineland-II) Two-domain Composite (2DC) Score. | Balovaptan | 4.56 | Standard Deviation 10.85 | Score | |
| Change From Baseline at Week 24 on the Vineland Adaptive Behavior Scales (Vineland-II) Two-domain Composite (2DC) Score. | Placebo | 6.83 | Standard Deviation 12.18 | Score | |
| Change From Baseline at Week 12 on the Vineland-II 2DC Score | Balovaptan | 3.47 | Standard Deviation 10.00 | Score | |
| Change From Baseline at Week 12 on the Vineland-II 2DC Score | Placebo | 4.85 | Standard Deviation 12.64 | Score | |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Total Score at Week 12 | 4.1 | Standard Deviation 11.2 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Total Score at Week 12 | 5.0 | Standard Deviation 10.2 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Psychosocial Health Summary Score at Week 12 | 4.9 | Standard Deviation 13.2 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Psychosocial Health Summary Score at Week 12 | 5.5 | Standard Deviation 12.7 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Physical Health Summary Score at Week 12 | 2.5 | Standard Deviation 13.3 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Physical Health Summary Score at Week 12 | 4.3 | Standard Deviation 12.3 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Total Score at Week 24 | 8.0 | Standard Deviation 13.7 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Total Score at Week 24 | 6.0 | Standard Deviation 11.6 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Psychosocial Health Summary Score at Week 24 | 10.0 | Standard Deviation 15.4 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Psychosocial Health Summary Score at Week 24 | 6.9 | Standard Deviation 14.1 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Balovaptan | Physical Health Summary Score at Week 24 | 4.3 | Standard Deviation 15.5 | Score |
| Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores | Placebo | Physical Health Summary Score at Week 24 | 4.4 | Standard Deviation 14.5 | Score |
| Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score | Balovaptan | Week 12 | 2.87 | Standard Deviation 6.99 | Score |
| Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score | Placebo | Week 12 | 3.99 | Standard Deviation 10.01 | Score |
| Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score | Balovaptan | Week 24 | 4.32 | Standard Deviation 8.43 | Score |
| Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score | Placebo | Week 24 | 5.26 | Standard Deviation 9.69 | Score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03504917/results